glp-1 therapy for diabetes GLP‐1 Receptor Agonist and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 - Chen - 2026 - Journal of the American Geriatrics Society Clinical Focus on GLP-1 Agonists

It is the first triple-hormone-receptor agonist to reach advanced clinical trials, activating three distinct metabolic pathways that individually would each justify their own drug development program

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

Retatrutide is a triple-receptor agonist peptide that targets GLP-1, GIP, and glucagon pathways, making it a compound of significant interest in metabolic research

Detailed Information: PureRawz provides detailed research summaries for each peptide on its website, including liraglutide

When someone hears that a drug was derived from a chemical found in lizard venom, the initial reaction can be skepticism

Available online at: February 4, 2026)